Litcius/Paper detail

Puerarin alleviates osteoporosis in the ovariectomy-induced mice by suppressing osteoclastogenesis via inhibition of TRAF6/ROS-dependent MAPK/NF-κB signaling pathways

Long Xiao, Mengdan Zhong, Yu Huang, Jie Zhu, Wenkai Tang, Danyong Li, Jiandong Shi, Aiqing Lu, Huilin Yang, Dechun Geng, Hong Li, Zhirong Wang

2020Aging176 citationsDOIOpen Access PDF

Abstract

osteoclast differentiation, hydroxyapatite resorption activity, and expression of osteoclastogenesis-related genes, such as NFATc1, MMP9, CTSK, Acp5 and c-Fos, in RANKL-induced bone marrow macrophages (BMMs) and RAW264.7 cells. It also reduced intracellular ROS levels by suppressing expression of TRAF6 and NADPH oxidase 1 (NOX1) and increasing expression of antioxidant enzymes such as heme oxygenase-1 (HO-1). Puerarin inhibited TRAF6/ROS-dependent activation of the MAPK and NF-κB signaling pathways in RANKL-induced RAW264.7 cells, and these effects were partially reversed by HO-1 silencing or TRAF6 overexpression. These findings suggest puerarin alleviates loss of bone mass in the OVX-model mice by suppressing osteoclastogenesis via inhibition of the TRAF6/ROS-dependent MAPK/NF-κB signaling pathway.

Topics & Concepts

PuerarinNF-κBMAPK/ERK pathwaySignal transductionCell biologyNFKB1OsteoporosisChemistryCancer researchPharmacologyMedicineEndocrinologyBiologyTranscription factorBiochemistryGeneAlternative medicinePathologyBone Metabolism and DiseasesBone health and osteoporosis researchGDF15 and Related Biomarkers
Puerarin alleviates osteoporosis in the ovariectomy-induced mice by suppressing osteoclastogenesis via inhibition of TRAF6/ROS-dependent MAPK/NF-κB signaling pathways | Litcius